Viking Therapeutics Emerges as Potential Acquisition Target in Biotech
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2026
0mins
Source: Fool
- Obesity Drug Market Potential: Viking Therapeutics' VK2735 demonstrated strong efficacy in a recent Phase 2 oral obesity study, with patients achieving an average weight loss of 12.2% over 13 weeks, indicating its competitive edge in the obesity market and likely attracting interest from large pharmaceutical companies.
- Clinical Trial Progress: Viking's Phase 3 VANQUISH obesity studies are fully enrolled, and management expects to initiate Phase 3 trials for the oral formulation later this year, which will further validate VK2735's market potential and drive up the company's valuation.
- Strong Financial Position: As of Q1 2026, Viking holds approximately $603 million in cash and investments, which is expected to fund operations into 2028, providing the company with flexibility during acquisition negotiations and reducing immediate financing pressures.
- Clear Acquisition Logic: If a larger pharmaceutical company believes VK2735 can compete effectively in the obesity and diabetes markets, acquiring Viking could be less costly than waiting for the asset to reach commercialization, although the success of such acquisitions remains unpredictable.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.810
Low
70.00
Averages
97.00
High
125.00
Current: 34.810
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Initiates Phase 1 Trial of VK3019 for Weight Loss
- Trial Initiation: Viking Therapeutics has announced the initiation of a Phase 1 single ascending dose clinical trial for VK3019, aimed at evaluating its safety, tolerability, and pharmacokinetics, marking a significant expansion in the company's weight loss treatment portfolio.
- Innovative Mechanism: VK3019, as a dual amylin and calcitonin receptor agonist, may be used in conjunction with GLP-1 or dual GLP-1/GIP agonists to enhance weight loss efficacy, addressing the demand for safe and sustainable weight loss solutions among patients.
- Supporting Preclinical Data: Preliminary studies indicate that Viking's DACRAs significantly reduced food intake and body weight in healthy rats and diet-induced obese mice, with body weight reductions of up to 8% observed within 72 hours, providing strong support for VK3019's clinical application.
- Diverse Treatment Options: Viking is also conducting Phase 3 VANQUISH studies for VK2735, exploring its use in patients with obesity and type 2 diabetes, with plans to introduce both oral and injectable formulations to enhance market competitiveness and patient adherence.
See More
US Indices Fluctuate as Micron Reports Strong Earnings
- Mixed Market Performance: The S&P 500 and Nasdaq 100 fell by 0.1% and 0.4%, respectively, while the Dow Jones rose by 0.4%, indicating rising investor concerns about the sustainability of the AI boom ahead of Micron's earnings report.
- Micron's Strong Earnings: Micron's Q3 earnings and revenue significantly exceeded expectations, leading to an 11% surge in after-hours trading, which not only alleviated concerns about overheating AI demand but also boosted benchmark indices in after-hours trading.
- JPMorgan Raises Targets: JPMorgan raised its S&P 500 target for 2026 from 7,200 to 7,800, implying over 5% upside potential from current levels, reflecting optimistic market expectations for the future, although the upward path may face multiple hurdles.
- Alphabet Replaces Verizon: Alphabet is set to replace Verizon in the Dow, highlighting ongoing investor interest in tech stocks and reflecting a strong focus on the AI sector, which may attract more capital into related stocks.
See More
VK3019 Human Trial Launch Sparks 7% Stock Surge
- Trial Launch: Viking Therapeutics announced the initiation of human trials for VK3019, resulting in a 7% stock surge on Wednesday, indicating strong market interest and potential for further development in obesity treatment.
- Trial Design Details: The trial is a single ascending dose study targeting healthy adults with a BMI of 30 or higher, aimed at evaluating VK3019's safety and tolerability while monitoring short-term weight changes, potentially offering a new option for weight management.
- Positive Analyst Reaction: Raymond James stated that the trial launch marks a significant pipeline expansion for the company, positioning it to benefit from growing interest in amylin-based treatments, and assigned a 'Strong Buy' rating on the stock.
- Surging Market Sentiment: Retail sentiment around VKTX jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing by 4000%, reflecting strong investor confidence in the company's future prospects.
See More
Viking Initiates Phase 1 Clinical Trial for VK3019 Weight Loss Treatment
- Clinical Trial Launch: Viking Therapeutics has announced the initiation of a Phase 1 single ascending dose clinical trial for VK3019, aimed at evaluating its safety, tolerability, and pharmacokinetics, marking a significant expansion in the company's weight loss treatment portfolio.
- Innovative Drug Mechanism: VK3019, as a dual amylin and calcitonin receptor agonist, may potentially be used in combination with GLP-1 or dual GLP-1/GIP agonists to enhance weight loss efficacy, addressing patients' needs for safe and sustainable weight management.
- Supporting Preclinical Data: Preliminary studies indicate that Viking's DACRAs significantly reduced food intake and body weight in healthy rats and diet-induced obese mice, with body weight reductions of up to 8% within 72 hours, providing strong support for VK3019's clinical application.
- Diverse Treatment Options: Viking is also conducting Phase 3 VANQUISH studies for VK2735, exploring various dosing regimens to improve treatment persistence, which is expected to offer patients more flexible long-term therapy options.
See More
Viking Therapeutics' Obesity Drug Market Outlook
- Clinical Trial Catalyst: Viking Therapeutics is set to release maintenance study data in Q3, which could provide crucial insights into the long-term use of its obesity drug VK2735, with positive results likely to enhance market competitiveness and attract more investor interest.
- Dual-Track Development Strategy: VK2735, a dual GLP-1/GIP receptor agonist, is advancing in both subcutaneous and oral formulations, and the growing market demand for such flexibility may allow Viking to stand out in competition against giants like Novo Nordisk and Eli Lilly.
- Sufficient Funding for Development: As of the end of Q1, Viking Therapeutics had a cash runway of $603 million, which is adequate to support all its R&D plans through 2027, ensuring ongoing investment and innovation in the obesity drug market.
- Optimistic Analyst Ratings: According to Koyfin, 18 out of 20 analysts covering VKTX rate it as 'Buy' or higher, with a 12-month average price target of $92.58, indicating a potential upside of about 166% from the last closing price, reflecting strong market confidence in its future performance.
See More
GLP-1 Drug Market Poised for Significant Growth
- Market Potential: Analysts at Grand View Research estimate that the global GLP-1 drug market will exceed $185 billion by 2033, with a compound annual growth rate of 12.4%, indicating significant growth potential that could transform the healthcare landscape.
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, generated $19.8 billion in revenue during Q1 2026, reflecting an impressive growth rate of 56%, showcasing the company's robust competitive position in the rapidly expanding GLP-1 market.
- Viking Therapeutics' Potential: Although Viking Therapeutics has no approved drugs yet, its GLP-1 drug VK2735 has shown promising results in clinical trials, and if approved, could significantly boost its market value and become an attractive acquisition target for larger healthcare firms.
- Investment Risks and Opportunities: While Eli Lilly's high valuation at a 39x P/E ratio may seem steep, its strong fundamentals make it a compelling long-term investment, whereas Viking Therapeutics presents a higher risk-reward profile, appealing to investors looking for diversification.
See More
Viking Initiates Phase 1 Trial of VK3019 for Weight Loss
- Trial Initiation: Viking Therapeutics has announced the initiation of a Phase 1 single ascending dose clinical trial for VK3019, aimed at evaluating its safety, tolerability, and pharmacokinetics, marking a significant expansion in the company's weight loss treatment portfolio.
- Innovative Mechanism: VK3019, as a dual amylin and calcitonin receptor agonist, may be used in conjunction with GLP-1 or dual GLP-1/GIP agonists to enhance weight loss efficacy, addressing the demand for safe and sustainable weight loss solutions among patients.
- Supporting Preclinical Data: Preliminary studies indicate that Viking's DACRAs significantly reduced food intake and body weight in healthy rats and diet-induced obese mice, with body weight reductions of up to 8% observed within 72 hours, providing strong support for VK3019's clinical application.
- Diverse Treatment Options: Viking is also conducting Phase 3 VANQUISH studies for VK2735, exploring its use in patients with obesity and type 2 diabetes, with plans to introduce both oral and injectable formulations to enhance market competitiveness and patient adherence.
See More
US Indices Fluctuate as Micron Reports Strong Earnings
- Mixed Market Performance: The S&P 500 and Nasdaq 100 fell by 0.1% and 0.4%, respectively, while the Dow Jones rose by 0.4%, indicating rising investor concerns about the sustainability of the AI boom ahead of Micron's earnings report.
- Micron's Strong Earnings: Micron's Q3 earnings and revenue significantly exceeded expectations, leading to an 11% surge in after-hours trading, which not only alleviated concerns about overheating AI demand but also boosted benchmark indices in after-hours trading.
- JPMorgan Raises Targets: JPMorgan raised its S&P 500 target for 2026 from 7,200 to 7,800, implying over 5% upside potential from current levels, reflecting optimistic market expectations for the future, although the upward path may face multiple hurdles.
- Alphabet Replaces Verizon: Alphabet is set to replace Verizon in the Dow, highlighting ongoing investor interest in tech stocks and reflecting a strong focus on the AI sector, which may attract more capital into related stocks.
See More
VK3019 Human Trial Launch Sparks 7% Stock Surge
- Trial Launch: Viking Therapeutics announced the initiation of human trials for VK3019, resulting in a 7% stock surge on Wednesday, indicating strong market interest and potential for further development in obesity treatment.
- Trial Design Details: The trial is a single ascending dose study targeting healthy adults with a BMI of 30 or higher, aimed at evaluating VK3019's safety and tolerability while monitoring short-term weight changes, potentially offering a new option for weight management.
- Positive Analyst Reaction: Raymond James stated that the trial launch marks a significant pipeline expansion for the company, positioning it to benefit from growing interest in amylin-based treatments, and assigned a 'Strong Buy' rating on the stock.
- Surging Market Sentiment: Retail sentiment around VKTX jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing by 4000%, reflecting strong investor confidence in the company's future prospects.
See More
Viking Initiates Phase 1 Clinical Trial for VK3019 Weight Loss Treatment
- Clinical Trial Launch: Viking Therapeutics has announced the initiation of a Phase 1 single ascending dose clinical trial for VK3019, aimed at evaluating its safety, tolerability, and pharmacokinetics, marking a significant expansion in the company's weight loss treatment portfolio.
- Innovative Drug Mechanism: VK3019, as a dual amylin and calcitonin receptor agonist, may potentially be used in combination with GLP-1 or dual GLP-1/GIP agonists to enhance weight loss efficacy, addressing patients' needs for safe and sustainable weight management.
- Supporting Preclinical Data: Preliminary studies indicate that Viking's DACRAs significantly reduced food intake and body weight in healthy rats and diet-induced obese mice, with body weight reductions of up to 8% within 72 hours, providing strong support for VK3019's clinical application.
- Diverse Treatment Options: Viking is also conducting Phase 3 VANQUISH studies for VK2735, exploring various dosing regimens to improve treatment persistence, which is expected to offer patients more flexible long-term therapy options.
See More
Viking Therapeutics' Obesity Drug Market Outlook
- Clinical Trial Catalyst: Viking Therapeutics is set to release maintenance study data in Q3, which could provide crucial insights into the long-term use of its obesity drug VK2735, with positive results likely to enhance market competitiveness and attract more investor interest.
- Dual-Track Development Strategy: VK2735, a dual GLP-1/GIP receptor agonist, is advancing in both subcutaneous and oral formulations, and the growing market demand for such flexibility may allow Viking to stand out in competition against giants like Novo Nordisk and Eli Lilly.
- Sufficient Funding for Development: As of the end of Q1, Viking Therapeutics had a cash runway of $603 million, which is adequate to support all its R&D plans through 2027, ensuring ongoing investment and innovation in the obesity drug market.
- Optimistic Analyst Ratings: According to Koyfin, 18 out of 20 analysts covering VKTX rate it as 'Buy' or higher, with a 12-month average price target of $92.58, indicating a potential upside of about 166% from the last closing price, reflecting strong market confidence in its future performance.
See More
GLP-1 Drug Market Poised for Significant Growth
- Market Potential: Analysts at Grand View Research estimate that the global GLP-1 drug market will exceed $185 billion by 2033, with a compound annual growth rate of 12.4%, indicating significant growth potential that could transform the healthcare landscape.
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, generated $19.8 billion in revenue during Q1 2026, reflecting an impressive growth rate of 56%, showcasing the company's robust competitive position in the rapidly expanding GLP-1 market.
- Viking Therapeutics' Potential: Although Viking Therapeutics has no approved drugs yet, its GLP-1 drug VK2735 has shown promising results in clinical trials, and if approved, could significantly boost its market value and become an attractive acquisition target for larger healthcare firms.
- Investment Risks and Opportunities: While Eli Lilly's high valuation at a 39x P/E ratio may seem steep, its strong fundamentals make it a compelling long-term investment, whereas Viking Therapeutics presents a higher risk-reward profile, appealing to investors looking for diversification.
See More
